CC Community News Digest (January 3-9)

Assorted news from the last two weeks:

Children with chronic health conditions, including cancer, and those with special education needs, should receive more help with online learning.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Oncoheroes Biosciences, Inc., a clinical-stage biotechnology company advancing new therapies for childhood cancers, today announced that they have entered into licensing agreements under which Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates dovitinib, a pan-targeted kinase inhibitor (pan-TKI), and stenoparib, a PARP inhibitor, and assume responsibility for their further clinical development in pediatric cancers.

List of Cure Today’s top five childhood cancer stories from the last year.

Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.

 

Upcoming Webinars and Online Opportunities:

VIVA Foundation for Children with Cancer in collaboration with the St. Jude Children’s Research Hospital will host a new webinar series that will focus on childhood cancer survivorship care to educate health care professionals about medical and psychosocial risks associated with childhood cancer and its therapy.  The second episode airs on Friday, January 7 at 3:00ET and will cover Cardiac and Pulmonary Late Effects.  Registration link pending.
Please register to attend the 10th ACCELERATE Paediatric Oncology Conference, February 10-11 2022 (EU afternoons, US mornings).  The annual ACCELERATE Conference aims to strengthen international cooperation between academia, parent groups, biopharma companies, regulatory bodies and HTA bodies to improve and speed up the global development of new paediatric oncology drugs.